Towards a human oral vaccine for anthrax: The utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategy
- 11 November 2008
- journal article
- Published by Elsevier BV in Vaccine
- Vol. 26 (48), 6083-6091
- https://doi.org/10.1016/j.vaccine.2008.09.010
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Human Monoclonal Antibodies against Anthrax Lethal Factor and Protective Antigen Act Independently To Protect againstBacillus anthracisInfection and Enhance Endogenous Immunity to AnthraxInfection and Immunity, 2007
- Enhanced Immunity toPlasmodium falciparumCircumsporozoite Protein (PfCSP) by UsingSalmonella entericaSerovar Typhi Expressing PfCSP and a PfCSP-Encoding DNA Vaccine in a Heterologous Prime-Boost StrategyInfection and Immunity, 2007
- Oral Administration of a Salmonella enterica -Based Vaccine Expressing Bacillus anthracis Protective Antigen Confers Protection against Aerosolized B. anthracisInfection and Immunity, 2007
- Immunogenicity of Recombinant Protective Antigen and Efficacy against Aerosol Challenge with AnthraxInfection and Immunity, 2005
- Recombinant Salmonella enterica serovar Typhi in a prime-boost strategyVaccine, 2004
- Salmonella enterica Serovar Typhimurium Expressing a Chromosomally Integrated Copy of the Bacillus anthracis Protective Antigen Gene Protects Mice against an Anthrax Spore ChallengeInfection and Immunity, 2003
- Salmonellavaccines for use in humans: present and future perspectivesFEMS Microbiology Reviews, 2002
- Mucosal or Parenteral Administration of Microsphere-Associated Bacillus anthracis Protective Antigen Protects against Anthrax Infection in MiceInfection and Immunity, 2002
- Delivering death in the mailNature, 2001
- Production and purification of recombinant protective antigen and protective efficacy against Bacillus anthracisLetters in Applied Microbiology, 1998